Diabetes Mellitus and Atrial Remodeling: Mechanisms and Potential Upstream Therapies

Cardiovascular Therapeutics

Volumn 32, Issue 5, 2014, Pages 233-241

  Zhang, Qitong ^a   Liu, Tong ^a   Ng, Chee Y ^b   Li, Guangping ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation; Atrial remodeling; Diabetes mellitus; Mechanisms; Upstream therapies

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBUCOL;

AGONISTS; ATRIAL FIBRILLATION; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HEART ATRIUM REMODELING; HUMAN; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; ATRIAL REMODELING; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; OXIDATIVE STRESS; PPAR GAMMA; PROBUCOL; RECEPTORS, IMMUNOLOGIC;

EID: 84908396474     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12089     Document Type: Review

References (87)

1. Korantzopoulos P, Liu T, Milionis HJ, Li G, Goudevenos JA. "Lone" atrial fibrillation: hunting for the underlying causes and links. Int J Cardiol 2009;131:180-185.
2. Liu T, Fu Z, Korantzopoulos P, Zhang X, Wang S, Li G. Effect of obesity on p-wave parameters in a chinese population. Ann Noninvasive Electrocardiol 2010;15:259-263.
3. Ng CY, Liu T, Shehata M, Stevens S, Chugh SS, Wang X. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol 2011;108:47-51.
4. Korantzopoulos P, Kokkoris S, Liu T, Protopsaltis I, Li G, Goudevenos JA. Atrial fibrillation in end-stage renal disease. Pacing Clin Electrophysiol 2007;30:1391-1397.
5. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011;108:56-62.
6. Klem I, Wehinger C, Schneider B, Hartl E, Finsterer J, Stollberger C. Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. Diabetes Metab Res Rev 2003;19:320-328.
7. Ostgren CJ, Merlo J, Rastam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a swedish community. Diabetes Obes Metab 2004;6:367-374.
8. Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 2010;25:853-858.
9. Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 2009;32:1851-1856.
10. Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am Coll Cardiol 2012;60:1421-1428.
11. Huxley RR, Alonso A, Lopez FL, et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities Study. Heart 2012;98:133-138.
12. Kato T, Yamashita T, Sekiguchi A, et al. What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol 2006;17:890-894.
13. Liu C, Fu H, Li J, et al. Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits. Anadolu Kardiyol Derg 2012;12:543-550.
14. Dudley SC Jr, Hoch NE, McCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the nadph and xanthine oxidases. Circulation 2005;112:1266-1273.
15. Neuman RB, Bloom HL, Shukrullah I, et al. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 2007;53:1652-1657.
16. Kim YM, Guzik TJ, Zhang YH, et al. A myocardial nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005;97:629-636.
17. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, Neufer PD. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 2009;54:1891-1898.
18. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996;93:1905-1912.
19. Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007;9:1146-1155.
20. Brownlee M, Cerami A. The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem 1981;50:385-432.
21. Sandau K, Pfeilschifter J, Brune B. Nitric oxide and superoxide induced p53 and bax accumulation during mesangial cell apoptosis. Kidney Int 1997;52:378-386.
22. Bern MM. Platelet functions in diabetes mellitus. Diabetes 1978;27:342-350.
23. Mahajan N, Dhawan V. Receptor for advanced glycation end products (RAGE) in vascular and inflammatory diseases. Int J Cardiol 2013;168:1788-1794.
24. Yamagishi S, Adachi H, Nakamura K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006;55:1227-1231.
25. Choi KM, Yoo HJ, Kim HY, et al. Association between endogenous secretory rage, inflammatory markers and arterial stiffness. Int J Cardiol 2009;132:96-101.
26. Twigg SM, Joly AH, Chen MM, et al. Connective tissue growth factor/igf-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 2002;143:1260-1269.
27. Twigg SM, Cao Z, MCLennan SV, et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002;143:4907-4915.
28. van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008;117:43-51.
29. Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003;92:785-792.
30. Kato T, Yamashita T, Sekiguchi A, et al. Ages-rage system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 2008;19:415-420.
31. Zhang Q, Li G, Liu T. Receptor for advanced glycation end products (RAGE): novel biomarker and therapeutic target for atrial fibrillation. Int J Cardiol 2013;168:4802-4804.
32. Watanabe M, Yokoshiki H, Mitsuyama H, Mizukami K, Ono T, Tsutsui H. Conduction and refractory disorders in the diabetic atrium. Am J Physiol Heart Circ Physiol 2012;303:H86-H95.
33. Igarashi T, Finet JE, Takeuchi A, et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation 2012;125:216-225.
34. Chao TF, Suenari K, Chang SL, et al. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J Cardiol 2010;106:1615-1620.
35. Ayhan S, Ozturk S, Alcelik A, et al. Atrial conduction time and atrial mechanical function in patients with impaired fasting glucose. J Interv Card Electrophysiol 2012;35:247-252.
36. Acar G, Akcay A, Sokmen A, et al. Assessment of atrial electromechanical delay, diastolic functions, and left atrial mechanical functions in patients with type 1 diabetes mellitus. J Am Soc Echocardiogr 2009;22:732-738.
37. Daubert JC, Pavin D, Jauvert G, Mabo P. Intra- and interatrial conduction delay: implications for cardiac pacing. Pacing Clin Electrophysiol 2004;27:507-525.
38. Di Cori A, Di Bello V, Miccoli R, et al. Left ventricular function in normotensive young adults with well-controlled type 1 diabetes mellitus. Am J Cardiol 2007;99:84-90.
39. Fu H, Liu C, Li J, et al. Impaired atrial electromechanical function and atrial fibrillation promotion in alloxan-induced diabetic rabbits. Cardiol J 2013;20:59-67.
40. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008;51:802-809.
41. Aldhoon B, Melenovsky V, Peichl P, Kautzner J. New insights into mechanisms of atrial fibrillation. Physiol Res 2010;59:1-12.
42. Arora R. Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: implications for therapies targeting the atrial autonomic nervous system. Circ Arrhythm Electrophysiol 2012;5:850-859.
43. Saito F, Kawaguchi M, Izumida J, Asakura T, Maehara K, Maruyama Y. Alteration in haemodynamics and pathological changes in the cardiovascular system during the development of type 2 diabetes mellitus in oletf rats. Diabetologia 2003;46:1161-1169.
44. McDowell TS, Chapleau MW, Hajduczok G, Abboud FM. Baroreflex dysfunction in diabetes mellitus. I. Selective impairment of parasympathetic control of heart rate. Am J Physiol 1994;266:H235-H243.
45. Lin M, Ai J, Harden SW, et al. Impairment of baroreflex control of heart rate and structural changes of cardiac ganglia in conscious streptozotocin (stz)-induced diabetic mice. Auton Neurosci 2010;155:39-48.
46. Dall'ago P, D'Agord Schaan B, da Silva VO, et al. Parasympathetic dysfunction is associated with baroreflex and chemoreflex impairment in streptozotocin-induced diabetes in rats. Auton Neurosci 2007;131:28-35.
47. Qin F, Vulapalli RS, Stevens SY, Liang CS. Loss of cardiac sympathetic neurotransmitters in heart failure and ne infusion is associated with reduced ngf. Am J Physiol Heart Circ Physiol 2002;282:H363-H371.
48. Schmid H, Forman LA, Cao X, Sherman PS, Stevens MJ. Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: implications for cardiac sympathetic dysinnervation complicating diabetes. Diabetes 1999;48:603-608.
49. Oberhauser V, Schwertfeger E, Rutz T, Beyersdorf F, Rump LC. Acetylcholine release in human heart atrium: influence of muscarinic autoreceptors, diabetes, and age. Circulation 2001;103:1638-1643.
50. Mabe AM, Hoover DB. Remodeling of cardiac cholinergic innervation and control of heart rate in mice with streptozotocin-induced diabetes. Auton Neurosci 2011;162:24-31.
51. Otake H, Suzuki H, Honda T, Maruyama Y. Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. Int Heart J 2009;50:627-641.
52. Lin Y, Li H, Lan X, Chen X, Zhang A, Li Z. Mechanism of and therapeutic strategy for atrial fibrillation associated with diabetes mellitus. Sci World J 2013;2013:209428.
53. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for european society of cardiology guidelines. Part I: primary prevention. Europace 2011;13:308-328.
54. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for european society of cardiology guidelines. Part II: secondary prevention. Europace 2011;13:610-625.
55. Palee S, Chattipakorn S, Phrommintikul A, Chattipakorn N. Ppargamma activator, rosiglitazone: is it beneficial or harmful to the cardiovascular system? World J Cardiol 2011;3:144-152.
56. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and ppargamma agonists: time for a reassessment. Trends Endocrinol Metab 2012;23:205-215.
57. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
58. Chao TF, Leu HB, Huang CC, et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol 2012;156:199-202.
59. Gu J, Liu X, Wang X, et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace 2011;13:1256-1261.
60. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188.
61. Liu T, Korantzopoulos P, Li G, Li J. The potential role of thiazolidinediones in atrial fibrillation. Int J Cardiol 2008;128:129-130.
62. Liu T, Li G. Thiazolidinediones as novel upstream therapy for atrial fibrillation in diabetic patients: a review of current evidence. Int J Cardiol 2012;156:215-216.
63. Shimano M, Tsuji Y, Inden Y, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008;5:451-459.
64. Kume O, Takahashi N, Wakisaka O, et al. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm 2011;8:278-285.
65. Xu D, Murakoshi N, Igarashi M, et al. Ppar-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. J Cardiovasc Electrophysiol 2012;23:209-217.
66. Nakajima T, Iwasawa K, Oonuma H, et al. Troglitazone inhibits voltage-dependent calcium currents in guinea pig cardiac myocytes. Circulation 1999;99:2942-2950.
67. Liu T, Zhao H, Li J, et al. Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits. Cardiovasc Ther 2014;32:178-183.
68. Liu T, Li G. Probucol and succinobucol in atrial fibrillation: pros and cons. Int J Cardiol 2010;144:295-296.
69. Gong YT, Li WM, Li Y, et al. Probucol attenuates atrial autonomic remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Chin Med J (Engl) 2009;122:74-82.
70. Li Y, Sheng L, Li W, et al. Probucol attenuates atrial structural remodeling in prolonged pacing-induced atrial fibrillation in dogs. Biochem Biophys Res Commun 2009;381:198-203.
71. Fu H, Liu T, Liu C, et al. Probucol preserves atrial structure and function by attenuates oxidative stress and increases stability of vulnerable atrial fibrillation in alloxan-induced diabetic rabbits. Cardiology 2012;123:48-49.
72. Ooie T, Takahashi N, Saikawa T, et al. Single oral dose of geranylgeranylacetone induces heat-shock protein 72 and renders protection against ischemia/reperfusion injury in rat heart. Circulation 2001;104:1837-1843.
73. Kato T, Yamashita T, Sekiguchi A, et al. Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling. J Cardiol 2011;58:131-136.
74. Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ace inhibition in experimental diabetic nephropathy. Diabetes 2002;51:3274-3282.
75. Miyata T, van Ypersele de Strihou C, Ueda Y, et al. Angiotensin ii receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002;13:2478-2487.
76. Lee CI, Guh JY, Chen HC, Hung WC, Yang YL, Chuang LY. Advanced glycation end-product-induced mitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in nrk-49f cells. J Cell Biochem 2005;95:281-292.
77. Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H. Angiotensin ii augments advanced glycation end product-induced pericyte apoptosis through rage overexpression. FEBS Lett 2005;579:4265-4270.
78. Fujita M, Okuda H, Tsukamoto O, et al. Blockade of angiotensin ii receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol 2006;26:e138-e142.
79. Liu T, Li G. Inflammation: another potential mechanism between diabetes mellitus and atrial fibrillation. Am J Cardiol 2008;101:1681-1682.
80. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a metaanalysis. J Am Coll Cardiol 2007;49:1642-1648.
81. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007;115:135-143.
82. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008;126:160-170.
83. Liu T, Li G, Korantzopoulos P, Goudevenos JA. Statins and prevention of atrial fibrillation in patients with heart failure. Int J Cardiol 2009;135:e83-e84.
84. Liu T, Korantzopoulos P, Shehata M, Li G, Wang X, Kaul S. Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trials. Heart 2011;97:1034-1040.
85. Liu T, Korantzopoulos P, Li G. Antioxidant therapies for the management of atrial fibrillation. Cardiovasc Diagn Ther 2012;2:298-307.
86. Sovari AA, Dudley SC Jr. Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation. Front Physiol 2012;3:311.
87. Korantzopoulos P, Kolettis TM, Kountouris E, et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 2005;102:321-326.